SCHEMBL1744909

SCHEMBL1744909

CC1(C)CC(CNc2nc(Nc3ccc4c(c3)-n3nnnc3C(C)(C)O4)ncc2F)C(C)(C)N1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKCQ Q04759 11/20 0.43
SYK P43405 8/20 0.39
EGFR P00533 2/20 0.34
BMPR1B O00238 1/20 0.34
CDC7 O00311 1/20 0.34
PIK3CD O00329 1/20 0.34
PLK4 O00444 1/20 0.34
STK25 O00506 1/20 0.34
CIT O14578 1/20 0.34
RIOK3 O14730 1/20 0.34
CHEK1 O14757 1/20 0.34
IKBKB O14920 1/20 0.34
AURKA O14965 1/20 0.34
GAK O14976 1/20 0.34
CHUK O15111 1/20 0.34
MUSK O15146 1/20 0.34
EPHB6 O15197 1/20 0.34
MAPK13 O15264 1/20 0.34
PDPK1 O15530 1/20 0.34
DAPK3 O43293 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1743860 0.88 PRKCQ (0.41) PRKCQSYKEGFRBMPR1BCDC7
SCHEMBL1745628 0.88 PRKCQ (0.41) PRKCQSYKEGFRBMPR1BCDC7
SCHEMBL1742898 0.87 PRKCQ (0.49) PRKCQSYKEGFRITK
SCHEMBL1745633 0.87 PRKCQ (0.43) PRKCQSYKEGFRITK
SCHEMBL1743698 0.86 PRKCQ (0.47) PRKCQSYKEGFRBMPR1BCDC7
SCHEMBL15770080 0.82 PRKCQ (0.46) PRKCQSYKEGFR
SCHEMBL1743613 0.80 PRKCQ (0.58) PRKCQSYKEGFRCDC7PLK4
SCHEMBL1744556 0.79 PRKCQ (0.47) PRKCQSYKEGFRJAK2ULK1
SCHEMBL17082793 0.77 PRKCQ (0.48) PRKCQSYKEGFRBMPR1BCDC7
SCHEMBL15322379 0.75 PRKCQ (0.44) PRKCQSYKEGFRULK1BMX

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8394951-B2 Protein kinase C inhibitors and uses thereof RIGEL PHARMACEUTICALS INC. (US) 2013-03-12 US claimed
EP-2387572-A2 PROTEIN KINASE C INHIBITORS AND USES THEREOF Rigel Pharmaceuticals, Inc. (US) 2011-11-23 EP claimed
US-8040334-B2 Method of driving display device 02MICRO INTERNATIONAL LIMITED (KY) 2011-10-18 US claimed
WO-2010083207-A2 PROTEIN KINASE C INHIBITORS AND USES THEREOF RIGEL PHARMACEUTICALS, INC. (US) 2010-07-22 WO claimed
US-20100184755-A1 PROTEIN KINASE C INHIBITORS AND USES THEREOF MIDCAP FINANCIAL TRUST 2010-07-22 US claimed
US-10736892-B2 Stem cell modulation II EpiAxis Therapeutics Pty Ltd. (AU) 2020-08-11 US disclosed
US-9453028-B2 Protein kinase C inhibitors and uses thereof RIGEL PHARMACEUTICALS, INC. (US) 2016-09-27 US disclosed
US-20150376203-A1 Protein Kinase C Inhibitors and Uses Thereof MIDCAP FINANCIAL TRUST 2015-12-31 US disclosed
EP-2387572-B1 PROTEIN KINASE C INHIBITORS AND USES THEREOF RIGEL PHARMACEUTICALS INC (US) 2015-09-16 EP disclosed
US-9095593-B2 Protein kinase C inhibitors and uses thereof RIGEL PHARMACEUTICALS, INC. (US) 2015-08-04 US disclosed
US-20130143875-A1 Protein Kinase C Inhibitors and Uses Thereof RIGEL PHARMACEUTICALS, INC. (US) 2013-06-06 US disclosed
US-8394951-B2 Protein kinase C inhibitors and uses thereof RIGEL PHARMACEUTICALS INC. (US) 2013-03-12 US disclosed
EP-2387572-A2 PROTEIN KINASE C INHIBITORS AND USES THEREOF Rigel Pharmaceuticals, Inc. (US) 2011-11-23 EP disclosed
US-8040334-B2 Method of driving display device 02MICRO INTERNATIONAL LIMITED (KY) 2011-10-18 US disclosed
WO-2010083207-A2 PROTEIN KINASE C INHIBITORS AND USES THEREOF RIGEL PHARMACEUTICALS, INC. (US) 2010-07-22 WO disclosed
US-20100184755-A1 PROTEIN KINASE C INHIBITORS AND USES THEREOF MIDCAP FINANCIAL TRUST 2010-07-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10736892-B2 Stem cell modulation II PRKCQ, PRKCI, PRKCG PRKCQ 1/4885SYK 2245/4885EGFR 1255/4885
US-20150376203-A1 Protein Kinase C Inhibitors and Uses Thereof PRKCH, PRKCA, PRKCB PRKCQ 5/4885SYK 600/4885EGFR 2299/4885
US-20130143875-A1 Protein Kinase C Inhibitors and Uses Thereof PRKCH, PRKCA, PRKCB PRKCQ 5/4885SYK 600/4885EGFR 2299/4885
US-20100184755-A1 PROTEIN KINASE C INHIBITORS AND USES THEREOF PRKCH, PRKCA, PRKCB PRKCQ 5/4885SYK 600/4885EGFR 2299/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.